Alex Matter, CEO of Experimental Therapeutics Center, Singapore.

He is best known for his contribution to the development of Glivec/ Gleevec, one of the world’s first tyrosine kinase inhibitor drugs against chronic myeloid leukemia (CML).

Alex was the founding director of the Novartis Institute for Tropical Diseases in 2003. He was a member of the Scientific Advisory Board of the Institute of Molecular and Cell Biology (IMCB) since 2005, a member of the A*STAR Investigatorship Selection Panel in 2007, and a member of the Experimental Therapeutics Centre Project Review Committee in 2008. His previous positions include Head of Cancer research at Hoffman-La Roche, Head of Cancer and Virology Research at CIBA-GEIGY and Global Head of Oncology Research, at Novartis. Dr Matter co-founded the Esperanza Medicines Foundation, a non-profit organization that aims to develop affordable drugs for treatment and prevention of AIDS in developing countries.

Alex is an MD from the University of Basel and conducted immunology and pathology research in Switzerland, Britain, France and the United States of America before entering into the pharmaceutical industry.

Ma Hui Hsing, General Partner TVM Capital
 

Hui Hsing has worked with TVM Capital since 2004 and joined the Life Science team as a  Venture Partner in 2007.

She entered the life sciences industry in 2000 when she was a Senior Vice President at Vertex Management, where she co-led the Global Biotechnology Investment Division. Since 2003, she has been advising life sciences businesses wishing to expand or raise funds in Asia. Prior to 2000, she accumulated over 16 years of international investment, corporate finance and general management experience with Singapore Technologies, Banque Nationale de Paris, General Electric (USA), Morgan Grenfell, Booz, Allen & Hamilton and Price Waterhouse.

Hui Hsing holds a MSc in Biotechnology from the Johns Hopkins University, USA, a MBA from Manchester Business School, UK and a Bachelor of Accountancy from the National University of Singapore.

Robert Teoh, MBBS MD FRCP, Founder & Managing Director of Pacific Clinical Research, a Pan-Asian clinical research organization,

Robert has over 20 years experience in the bio-pharmaceutical and CRO industries in Asia, Switzerland & the USA, having sold his two earlier pan-Asian CROs, ProPharma, and Pacific Pharma Partners, as profitable and growing concerns to PPD (NASDAQ: PPDI) and i3 Research, a unit of United Health (NYSE: UNH), respectively. Robert started Quintiles in East Asia and previously worked at Sandoz (now Novartis) in Hong Kong & Switzerland, and Tanox Inc in the USA. He sat on the boards of CombinatoRx Singapore (a joint venture between CombinatoRx Inc & Bio-1 Capital), and the Institute of Molecular & Cell Biology and on advisory committees of Singapore’s Economic Development Board and National Science & Technology Board.    

Robert qualified in medicine from the University of Newcastle upon Tyne, England and trained in neurology in London at the National Hospital for Nervous Diseases, Royal Postgraduate Medical School, Hammersmith Hospital, and Guys Hospital.  Following a UK Medical Research Council fellowship, he held faculty positions at Johns Hopkins University, Baltimore, and a tenured post at the Chinese University of Hong Kong.  He has published over 55 papers in peer reviewed journals and three chapters in books.